Oxford Biomedica (OXB) Share Price, News & Analysis

Company Overview

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

Key Stats

• Today's Range: 576 to 592
• 50-Day Range: 357 to 602
• 52-Week Range: 232.50 to 613.15
• Volume: 1.63 million shs
• Average Volume: 274,763 shs
• Market Capitalization: £711.47 million
• P/E Ratio: N/A
• Dividend Yield: 4.57%
• Price Target: GBX 540.25
• Consensus Rating: Moderate Buy

Oxford Biomedica Stock Analysis - MarketRank™

Oxford Biomedica scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oxford Biomedica has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Downside Risk

Oxford Biomedica has a consensus price target of GBX 540.25, representing about 8.7% downside from its current price of GBX 592.

Amount of Analyst Coverage

Oxford Biomedica has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oxford Biomedica is -1,417.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oxford Biomedica is -1,417.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oxford Biomedica has a P/B Ratio of 8.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OXB.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Oxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Oxford Biomedica does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OXB.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Oxford Biomedica to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Oxford Biomedica insiders have bought 1,221.50% more of their company's stock than they have sold. Specifically, they have bought £301,500 in company stock and sold £22,815 in company stock.

Percentage Held by Insiders

43.30% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 32.41% of the stock of Oxford Biomedica is held by institutions.

OXB Stock Analysis - Frequently Asked Questions

How have OXB shares performed this year?

Oxford Biomedica's stock was trading at GBX 420 on January 1st, 2025. Since then, OXB stock has increased by 41.0% and is now trading at GBX 592.

How were Oxford Biomedica's earnings last quarter?

Oxford Biomedica plc (LON:OXB) released its quarterly earnings results on Wednesday, April, 9th. The biopharmaceutical company reported ($41.75) earnings per share for the quarter. Oxford Biomedica had a negative trailing twelve-month return on equity of 202.50% and a negative net margin of 145.98%.
Read the conference call transcript.

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford BioMedica (OXBDF) and Barclays (BARC).

Company Calendar

• Last Earnings: 4/09/2025
• Today: 9/19/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:OXB
• CIK: N/A
• Web: www.oxfordbiomedica.co.uk
• Phone: +44-1865-783000
• Fax: N/A
• Employees: 891
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oxford Biomedica: GBX 540.25
• High Price Target: GBX 930
• Low Price Target: GBX 380
• Potential Upside/Downside: -8.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£143.51 million
• Net Margins: -145.98%
• Pretax Margin: N/A
• Return on Equity: -202.50%
• Return on Assets: -12.67%

Debt

• Debt-to-Equity Ratio: 166.48
• Current Ratio: 2.35
• Quick Ratio: 1.67

Sales & Book Value

• Annual Sales: £128.80 million
• Price / Sales: 5.52
• Cash Flow: GBX 196.91 per share
• Price / Cash Flow: 3.01
• Book Value: GBX 67.70 per share
• Price / Book: 8.74

Miscellaneous

• Outstanding Shares: 120,181,000
• Free Float: N/A
• Market Cap: £711.47 million
• Optionable: Not Optionable
• Beta: 1.09